Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Marketed and Pipeline Drugs Report Overview
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a type of acquired immune-mediated disorder that affects the myelin components of the peripheral nervous system. CIDP can be monophasic, relapsing, or progressive, developing over eight weeks. People with CIDP experience fatigue, muscle weakness, and a loss of feeling symmetrically in their arms and legs that tends to slowly worsen over time.
The CIDP marketed and pipeline drugs market research report provides a data-driven overview of the current and future competitive landscape in CIDP therapeutics. This report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing, and reimbursement, late-stage pipeline products with phase transition success rate (PTSR), and the likelihood of approval (LoA) for CIDP.
Leading Marketed Drugs for CIDP
High-dose IVIg is the only drug that has approval in the US, Canada, and Europe for the treatment of CIDP. Other first-line options include corticosteroids and plasma exchange. Depending on the country, these therapies may be tried before opting for IVIg.
Top Market Players in the CIDP Marketed and Pipeline Drugs Market
A few of the top market players in the CIDP are Takeda, Octapharma, Immupharma, Argenx, Zai Lab, Johnson & Johnson, and Grifols.
CIDP Marketed and Pipeline Drugs Competitor Analysis
Buy the full Report for More Player Insights into the CIDP Marketed and Pipeline Drugs, Download a Free Report Sample
CIDP Marketed Drugs Segmentation by Mechanism of Action
The key mechanisms of action for CIDP marketed drugs are receptor agonist and enzyme inhibitor. Receptor agonist is the leading MoA.
CIDP Marketed Drugs Analysis, by Mechanism of Action
Buy the full Report for More MoA Insights into the CIDP Marketed Drugs, Download a Free Report Sample
CIDP Marketed Drugs Segmentation by Routes of Administration
The key routes of administration for CIDP marketed drugs are oral, injection, and topical. Oral is the most preferred mode of administration.
CIDP Marketed Drugs Analysis, by Routes of Administration
Buy the full Report for More RoA Insights into the CIDP Marketed Drugs, Download a Free Report Sample
CIDP Marketed Drugs Segmentation by Molecule Type
The key molecule types for marketed drugs for CIDP are small molecule and biologics. Among them, the small molecule is the leading one.
CIDP Marketed Drugs Analysis, by Molecule Type
Buy the full Report for More Molecule Type Insights into the CIDP Marketed Drugs, Download a Free Report Sample
CIDP Pipeline Drugs Segmentation by Mechanism of Action
A few of the key mechanisms of action for CIDP pipeline drugs are receptor antagonist, cytotoxic to cell, enzyme inhibitor, protein and peptide inhibitor, and receptor agonist. Receptor agonist is the leading MoA in the pipeline.
CIDP Pipeline Drugs Analysis, by Mechanisms of Action
Buy the full Report for More MoA Insights into the CIDP Pipeline Drugs, Download a Free Report Sample
Chronic Inflammatory Demyelinating Polyneuropathy Marketed and Pipeline Drugs Market
- On 10th Oct 2022, CSPC NBP Pharma Enters into Sub – Licensing Agreement with Harbour BioMed
- On 29th Nov 2021, ImmuPharma Enters into Agreement with Imperial College London
Buy the full Report for More Deal Insights into the CIDP Marketed and Pipeline Drugs, Download a Free Report Sample
| Key Mechanisms of Action (Marketed) | · Receptor Agonist
· Enzyme Inhibitor |
| Key Routes of Administration (Marketed) | · Topical
· Oral · Injection |
| Key Molecule Types (Marketed) | · Small Molecule
· Biologics |
| Key Mechanisms of Action (Pipeline) | · Receptor Antagonist
· Cytotoxic to Cell · Enzyme Inhibitor · Protein and Peptide Inhibitor · Receptor Agonist |
| Key Routes of Administration (Pipeline) | · Injection |
| Key Molecule Types (Pipeline) | · Biologics |
| Top Market Players
|
· Takeda
· Octapharma · Immupharma · Argenx · Zai Lab · Johnson & Johnson · Grifols. |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Segments Covered in the Report
CIDP Marketed Drugs MoA Outlook
- Receptor Agonist
- Enzyme Inhibitor
CIDP Marketed Drugs RoA Outlook
- Topical
- Oral
- Injection
CIDP Marketed Drugs Molecule Type Outlook
- Small Molecule
- Biologics
CIDP Pipeline Drugs MoA Outlook
- Receptor Antagonist
- Cytotoxic to Cell
- Enzyme Inhibitor
- Protein and Peptide Inhibitor
- Receptor Agonist
CIDP Pipeline Drugs RoA Outlook
- Injection
CIDP Pipeline Drugs Molecule Type Outlook
- Biologics
Scope
GlobalData’s CIDP Marketed and Pipeline Drugs Assessment, Clinical Trials, and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Retail or Manufacturer Price of Products
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the CIDP market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CIDP market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
What are the key mechanisms of action for CIDP marketed drugs?
The key mechanisms of action for CIDP marketed drugs are receptor agonist and enzyme inhibitor.
-
What are the key routes of administration for CIDP marketed drugs?
The key routes of administration for CIDP marketed drugs are topical, oral, and injection.
-
What are the key molecule types for CIDP marketed drugs?
The key molecule types for CIDP marketed drugs are small molecule and biologics.
-
What are the key mechanisms of action for CIDP pipeline drugs?
The key mechanisms of action in the CIDP pipeline drugs market are receptor agonist, cytotoxic to cell, enzyme inhibitor, protein and peptide inhibitor, and receptor agonist.
-
What are the key routes of administration for CIDP pipeline drugs?
The key route of administration in the CIDP pipeline drugs market is injection.
-
What are the key molecule types for CIDP pipeline drugs?
The key molecule type in the CIDP pipeline drugs market is biologics.
-
Who are the top sponsors for the CIDP marketed and pipeline drugs market?
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Sample Report
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
